Both in Pharmaceuticals
Phathom Pharmaceuticals vs Gyre Therapeutics
Over the past year PHAT returned −57.9% and GYRE returned −38.8%; their daily moves had a correlation of 0.19.
PHAT −57.9% GYRE −38.8%Growth of $1, one year, split-adjusted
| Metric | PHAT | GYRE |
|---|---|---|
| Price | $5.68 | $4.44 |
| Market cap | $461.7M | $470.8M |
| Today | −1.05% | 0.00% |
| 1 month | −16.2% | −37.3% |
| 6 months | −55.2% | −44.8% |
| Year to date | −65.8% | −37.1% |
| 1 year | −58.6% | −39.7% |
| Revenue growth (YoY) | +71.1% | −2.1% |
| Gross margin | 78.3% | 92.4% |
| Net margin | −16.4% | −40.1% |
| P/E (TTM) | — | — |
| Price / sales | 1.7× | 3.9× |
| Net cash | $17.6M | $74.8M |
| Dividend yield | — | — |
| Volatility (60d) | 72.0% | 88.3% |
| Short % of float | 17.5% | 11.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).